Indications
·Refractory type 2 diabetes(insulin resistance index≥3.0)
·Genetic obesity(POMC/LEPR gene defects)
Extended Indications
·Polycystic ovary syndrome(PCOS)with glucose metabolism abnormalities(OGTT 2h glucose reduction≥2 mmol/L)
·Stage ll diabetic nephropathy(UACR reduction≥30%)
Features &Clinical Trial Data
1 Triple-Target Mechanism:
·GLP-1R:Enhances glucose-dependent insulin secretion.
·GIPR:Central appetite suppression(40%reduction in hypothalamic NPY neuron activity)
·GCGR:Activates hepatic gluconeogenesis,28%increase
in basal metabolic rate(DEXA-verified)
2 Comparative Advantages:
·24-week HbA1c reduction:2.4%vs.1.9%for Tirzepatide (△=0.5%,P=0.013).
·Visceral fat reduction:31%vs.18%(MRI quantification).
3 Gastric Retention Controlled-Release Technology:24-hoursustained release,peak-trough ratio <30%(vs.>50%forconventional tablets).
4 Pivotal Trial(n=1,327):
·52-week sustained weight loss:30.1 kg(vs.20.3 kg for Tirzepatide group).
·NASH improvement(≥2-grade):58%(liver biopsy confirmed).
